Veracyte (VCYT) Tops Q3 EPS by 30c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts VCYT Hot Sheet
Join SI Premium – FREE
Veracyte (NASDAQ: VCYT) reported Q3 EPS of $0.33, $0.30 better than the analyst estimate of $0.03. Revenue for the quarter came in at $115.9 million versus the consensus estimate of $109.85 million.
GUIDANCE:
Veracyte sees FY2024 revenue of $442-445 million, versus the consensus of $436.3 million. In addition, the company now expects cash, cash equivalents and short-term investments at the end of the year to be $280 million to $285 million compared to prior guidance of $260 million to $270 million.
For earnings history and earnings-related data on Veracyte (VCYT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China Huaren Organic Products, Inc. (CHRN) Tops Q1 EPS by 29c
- Q.e.p. Co., Inc. (QEPC) Tops Q2 EPS by 197c
- Washington Federal (WAFD) Misses Q3 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
